Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Skepta and PUMA Launch Groundbreaking Collection 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
McDonald's China Faces Backlash for Food Hygiene Violations 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming 2016 BIO Investor Forum being held October 18-19, 2016 at the Westin St. Francis Hotel in San Francisco, California. Ocera’s presentation will take place in the Elizabethan B Room at 8:30 AM Pacific Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
OCRX-G
Contact: Susan Sharpe Ocera Therapeutics, Inc. [email protected] 919-328-1109
